NAV-240

Phase 2Small molecule

NNavigator Medicines, Inc.

NAV-240 is one of 7 small molecule programs targeting Hidradenitis Suppurativa (HS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hidradenitis Suppurativa (HS)Recruiting

Hidradenitis Suppurativa (HS)Phase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Hidradenitis Suppurativa (HS)

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Approved

1 2

Povorcitinib

Incyte

Phase 3

3 3

Bimzelx

UCB

Phase 2

1 4

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1 5

Tibulizumab

ZZura Bio Inc

Phase 2

1 6

Soquelitinib

CCorvus Pharmaceuticals, Inc.

Phase 1

1 7

NAV-240

NNavigator Medicines, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Hidradenitis Suppurativa (HS)

NCT07384975

Clinical

Trials by Indication[1]

Intravenous1 trial

A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.

Completed·NNavigator Medicines, Inc.·Phase 1·NCT06933043·24 enrolled

Hidradenitis Suppurativa (HS)1 trial

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

Recruiting·NNavigator Medicines, Inc.·Phase 2·NCT07384975·150 enrolled

Unspecified1 trial

Study of NAV-240 in Healthy Volunteers

Completed·NNavigator Medicines, Inc.·Phase 1·NCT06181786·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NAV-240. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NAV-240 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NAV-240. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Navigator Medicines, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNavigator Medicines, Inc.

NAV-240

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Intravenous1 trial

Hidradenitis Suppurativa (HS)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News